← Back to Search

CAR T-cell Therapy

CAR T-Cell Therapy for Blood Cancer

Phase 1
Recruiting
Led By Rayne Rouce, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of recurrent or refractory T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including various subtypes)
Age </=75 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This trial is testing an investigational combination of two ways of fighting disease, antibodies and T cells, to see if it can better control or cure T-cell leukemia or lymphoma.

Who is the study for?
This trial is for patients under 75 with recurrent T-cell blood cancers, suitable for stem cell transplant, and have a CD7-positive tumor. They must not have active infections or other recent cancers (except certain skin/breast/cervix cancers), be pregnant, or have severe heart/CNS issues.Check my eligibility
What is being tested?
The study tests a new therapy where T cells from the patient's blood are modified in the lab to fight cancer better. These cells are equipped with an anti-CD7 antibody and CD28 protein to help them last longer and kill more cancer cells.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune response, such as inflammation in various organs due to the modified T cells attacking normal tissue by mistake. Specific side effects will depend on how each patient's body reacts to these engineered T cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a type of T-cell lymphoma that has come back or didn't respond to treatment.
Select...
I am 75 years old or younger.
Select...
My tumor is CD7 positive.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with dose limiting toxicity
Secondary outcome measures
Overall Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: CD7.CAR/28zeta CAR T CellsExperimental Treatment1 Intervention
Three dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
1,001 Previous Clinical Trials
6,002,231 Total Patients Enrolled
The Methodist Hospital Research InstituteOTHER
271 Previous Clinical Trials
80,354 Total Patients Enrolled
Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
111 Previous Clinical Trials
2,796 Total Patients Enrolled

Media Library

CD7.CAR/28zeta CAR T cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03690011 — Phase 1
Acute Lymphoblastic Leukemia Research Study Groups: CD7.CAR/28zeta CAR T Cells
Acute Lymphoblastic Leukemia Clinical Trial 2023: CD7.CAR/28zeta CAR T cells Highlights & Side Effects. Trial Name: NCT03690011 — Phase 1
CD7.CAR/28zeta CAR T cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03690011 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much risk is associated with CD7.CAR/28zeta CAR T cells for those who receive them?

"Our team at Power gives CD7.CAR/28zeta CAR T cells a score of 1 due to its limited clinical data in regards to safety and efficacy, as this is only the first phase of its trial."

Answered by AI

What is the most populous sample size for this research?

"Affirmative. According to clinicaltrials.gov, the trial was initially posted on August 2nd 2021 and is currently recruiting patients for its study; 21 participants will be accepted between two medical sites. The last update occurred June 7th 2022."

Answered by AI

Are there any vacancies in this investigation for volunteers?

"According to clinicaltrials.gov, this medical research is still open for recruitment. The trial was initially published on August 2nd 2021 and modified most recently on June 7th 2022."

Answered by AI

What application is CD7.CAR/28zeta CAR T cells most frequently employed for?

"CAR T-cell therapy, specifically CD7.CAR/28zeta CAR T cells, is a popular treatment for multiple sclerosis and can also be used to address lymphoma of varying cell types, leukemia, myelocytic acute anemia, as well as retinoblastoma."

Answered by AI

What prior investigations have taken place regarding CD7.CAR/28zeta CAR T cells?

"Presently, 889 trials are underway for CD7.CAR/28zeta CAR T cells and 161 of those have advanced to Phase 3. Although the majority are taking place in Philadelphia, Pennsylvania, this therapeutic intervention is being studied in 28446 different locations worldwide."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
LaQuisa Hill 2021. "Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03690011.
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top